BCL2 and renal cell adenocarcinoma: Therefore, we subclassified RCC patients into three groups according to the Bcl-2 status and the response to immunotherapy: negative Bcl-2 expression and good response to immunotherapy, negative Bcl-2 expression and no response to immunotherapy, and positive Bcl-2 expression (all non-responders).